Billing Under the New Jersey Fertility Mandate: Horizon BCBS Auth and 4-Retrieval Cycle Tracking

New Jersey's infertility mandate dates to P.L.2001, c.236, approved August 31, 2001. From the start it required hospital service, medical service, health service, group health insurance and HMO contracts covering groups of more than 50 persons (with pregnancy-related benefits) to cover medically necessary infertility diagnosis and treatment, and the statute named in vitro fertilization, embryo transfer, artificial insemination, GIFT, ZIFT, ICSI and four completed egg retrievals per lifetime as covered services. IVF has never been an optional carve-out for those contracts. The 2001 act did let carriers limit IVF to patients who had used less expensive treatments, had not reached four completed retrievals and were 45 or younger. P.L.2023, c.258 (Assembly Bill 5235, signed January 12, 2024) rewrote those sections. It took effect on the first day of the seventh month after enactment and applies to contracts issued or renewed on or after that date.

For fertility practices serving New Jersey patients, the 2024 amendments change what a compliant denial looks like: age-based restrictions are prohibited, embryo transfers are no longer a countable benefit, and carrier utilization review must stay consistent with ASRM guidelines. Billing workflows built around the older rules, or around assumptions about which plans the mandate reaches, need to be checked against the amended statute. This guide covers the statutory framework, scope of covered services, applicable CPT and ICD-10 codes, carrier-specific authorization requirements, FET and PGT billing, same-sex and single patient protocols, and the most common billing errors causing denials under the expanded NJ mandate.

The 2024 Amendments: What Changed for NJ Fertility Billing

The mandate is codified in five parallel sections, one per carrier type: N.J.S.A. 17:48-6x (hospital service corporations), 17:48A-7w (medical service corporations), 17:48E-35.22 (health service corporations), 17B:27-46.1x (group health insurance) and 26:2J-4.23 (HMOs). P.L.2017, c.48 applied the requirement to the State Health Benefits Program and the School Employees' Health Benefits Program (N.J.S.A. 52:14-17.29v and 52:14-17.46.6g). The only coverage exclusion the 2001 act allowed for IVF was the religious-employer exclusion, which a carrier must grant on request when the coverage is contrary to the employer's bona fide religious tenets. That exclusion survives the 2024 amendments.

P.L.2023, c.258 amended all five carrier sections and both SHBP/SEHBP sections. As amended, covered contracts must cover any services related to infertility in accordance with ASRM guidelines and as determined by a physician, including diagnosis and diagnostic tests; medications; surgery; IUI; IVF, including IVF with donor eggs and IVF where the embryo is transferred to a gestational carrier; genetic testing; artificial insemination; ICSI; four completed egg retrievals; unlimited embryo transfers in accordance with ASRM guidelines, using single embryo transfer when recommended and deemed medically appropriate by a physician; and the medical costs of egg or sperm donors until the donor is released from treatment. The amendment deleted the words "per lifetime of the covered person" after the four-retrieval item and removed the age-45 condition; a contract may not restrict infertility coverage based on age. Infertility is now defined as a disease, condition or status characterized by the inability to achieve a successful pregnancy based on medical, sexual and reproductive history, age, physical findings or diagnostic testing; the need for medical intervention, including donor gametes or donor embryos, to achieve a pregnancy as an individual or with a partner; or, for patients having regular unprotected intercourse with no known etiology, evaluation beginning at 12 months (female partner under 35) or 6 months (35 or older). The definition may not be used to deny or delay treatment to any individual regardless of relationship status or sexual orientation. Carriers may still limit IVF to patients who have used less expensive, medically appropriate treatments as determined by a licensed physician, and may perform utilization review, provided all utilization review decisions are consistent with ASRM guidelines.

Which New Jersey Plans Are Subject to the Expanded Mandate

The NJ infertility mandate applies to fully insured contracts issued in New Jersey for groups of more than 50 persons that include pregnancy-related benefits. Individual and small-employer plans are not within these statutory sections: a small-employer section was in A5235 as introduced but was deleted by amendment before enactment. Do not assume mandate coverage for a patient on an individual or small-group policy; verify the fertility benefit in that plan's own documents. The mandate does not apply to self-funded employer health plans, which are governed by ERISA and preempted from state insurance mandates. Confirming plan funding type at initial patient eligibility verification is the single most important step in the NJ billing workflow — a self-funded Horizon BCBS NJ plan has no obligation to cover IVF under the state mandate, regardless of what the group size or New Jersey address would suggest.

State and local government plans — the New Jersey State Health Benefits Program (SHBP) and the School Employees' Health Benefits Program (SEHBP) — are governmental plans outside ERISA preemption. They carry their own statutory infertility requirement (N.J.S.A. 52:14-17.29v and 52:14-17.46.6g, added by P.L.2017, c.48 and amended by P.L.2023, c.258). Confirm the member's plan and benefit details with the SHBP/SEHBP eligibility line rather than applying commercial carrier rules.

Scope of Covered Services Under the NJ Mandate

• Infertility diagnostic workup: FSH (83001), LH (83002), estradiol (82670), AMH (82166), prolactin (84146), TSH (84443), antral follicle count by transvaginal ultrasound (76830), hysterosalpingography (catheter placement 58340 with radiological supervision and interpretation 74740) or saline infusion sonohysterography (58340 with 76831), semen analysis (89320, or 89322 when strict morphologic criteria are used; 89310 for motility and count only), diagnostic hysteroscopy (58555), diagnostic laparoscopy (49320; 58660 is the surgical laparoscopy code when lysis of adhesions is performed), and endometrial biopsy (58100)
• IUI (intrauterine insemination): sperm isolation (89260 simple prep; 89261 complex prep, per the documented lab method) and the insemination procedure (58322); plan-level IUI cycle requirements before IVF authorization may apply, but carriers may not impose IUI prerequisites that are clinically contraindicated for the specific patient
• IVF — complete fresh cycle: controlled ovarian stimulation including monitoring ultrasounds (76830 transvaginal, non-obstetric; 76817 is the obstetric transvaginal code and does not describe stimulation monitoring), serial estradiol (82670) and LH (83002) labs, oocyte retrieval (58970 + ultrasound guidance 76948), conventional insemination (89268), ICSI (89280 for ≤10 oocytes; 89281 for >10 oocytes), embryo culture (89250), extended culture to blastocyst (89272), and fresh embryo transfer (58974)
• Embryo and oocyte cryopreservation (89258, 89337): cryopreservation is not a listed service in the infertility statute, and N.J.A.C. 11:4-54.5 lets carriers exclude the costs of cryopreserving and storing sperm, eggs and embryos from the infertility benefit. Iatrogenic fertility preservation is a separate mandate: P.L.2019, c.306 requires the same large-group contracts (more than 50 persons) to cover standard fertility preservation services when a medically necessary treatment may cause iatrogenic infertility, and that law excludes storage of sperm or oocytes
• FET (frozen embryo transfer): embryo thaw and preparation (89352) and FET embryo transfer (58974); the amended statute covers unlimited embryo transfers in accordance with ASRM guidelines, using single embryo transfer when recommended and deemed medically appropriate by a physician; if the carrier requires authorization for FET, do not assume the originating retrieval authorization extends to it
• PGT (preimplantation genetic testing): embryo biopsy (89290 for ≤5 embryos; 89291 for >5 embryos); the amended statute lists genetic testing among covered services; ask each carrier whether PGT needs its own authorization and what clinical documentation it expects
• Permissible exclusions under N.J.A.C. 11:4-54.5 (the only exclusions the rule allows): reversal of voluntary sterilization; medical services for a surrogate who is not covered by the carrier's contract; costs of cryopreservation and storage of sperm, eggs and embryos; nonmedical costs of an egg or sperm donor (the donor's medical costs must be covered until release from treatment); experimental or investigational treatments; and ovulation and sperm testing kits. The rule dates from 2003 and still contains an age-46 IVF exclusion that P.L.2023, c.258 removed from the statute; where the two differ, apply the statute

CPT Code Reference for NJ Mandate Fertility Services

ICD-10 Diagnosis Coding for NJ Mandate Claims

ICD-10 coding accuracy is essential for NJ mandate claims. The primary diagnosis code routes the claim to the fertility benefit and validates medical necessity during adjudication. Unspecified or mismatched codes generate supplemental documentation requests that delay reimbursement and increase denial risk.

Primary infertility diagnosis codes: N97.0 (female infertility associated with anovulation — use for PCOS, hypothalamic dysfunction, anovulatory cycles; add E28.2 as secondary when PCOS is the confirmed etiology); N97.1 (female infertility of tubal origin — documented tubal occlusion, prior ectopic pregnancy, salpingectomy, or tubal ligation reversal); N97.2 (female infertility of uterine origin — uterine anomaly, Asherman's syndrome, submucosal fibroid as the documented primary cause); N97.8 (female infertility of other origin — etiology that does not map to a more specific N97 code); N97.9 (female infertility, unspecified — use only when no specific etiology is documented; the weakest code for medical necessity defense, and carriers may issue supplemental documentation requests when this code appears as primary). Male factor codes: N46.01 (organic azoospermia); N46.11 (organic oligospermia); N46.021–N46.029 (azoospermia by etiology); N46.121–N46.129 (oligospermia by etiology). Encounter codes: Z31.83 (encounter for assisted reproductive fertility procedure cycle) — the first-listed code on every IVF and FET cycle claim, ahead of the infertility codes above (ICD-10-CM Official Guidelines, Section I.C.21.c.15); Z31.41 (encounter for fertility testing) — for diagnostic workup claims only. For iatrogenic fertility preservation — pre-chemotherapy or pre-radiation oocyte or embryo cryopreservation — Z31.84 (encounter for fertility preservation procedure) is the first-listed code (the same guideline section allows it only in that position), followed by the oncology code (e.g., C50.x for breast cancer; C56.x for ovarian cancer; C81–C96 for lymphoid and hematopoietic cancers, including lymphomas). Never place N97.x infertility codes on iatrogenic preservation claims. For same-sex and single patients with no documented infertility diagnosis: list Z31.83 first with Z31.89 (encounter for other procreative management) after it; when a co-existing infertility diagnosis is present, list Z31.83 first with the specific N97.x code after it.

Prior Authorization by Major New Jersey Carrier

• Horizon Blue Cross Blue Shield of New Jersey — Horizon's fully insured contracts for groups of more than 50 are subject to the NJ mandate. Confirm whether Horizon requires authorization for the specific service and product, and ask which documentation it expects; a typical package includes the confirmed infertility diagnosis and etiology meeting the NJ statutory definition, prior treatment history (IUI cycle outcomes or written documentation of clinical contraindication), the treating REI physician's signed treatment plan, and ovarian reserve testing results. Confirm the authorization validity period and whether an FET from an existing retrieval needs its own authorization; do not assume the retrieval authorization extends to later FET cycles. Verify the correct PA submission pathway at every eligibility call, as Horizon's product-level PA delegation can vary by group contract. For time-sensitive cycles, ask about expedited review and document the clinical urgency.
• Aetna New Jersey — Aetna publishes its national infertility clinical criteria in Clinical Policy Bulletin 0327; on a fully insured NJ large-group contract, the NJ statute and N.J.A.C. 11:4-54.3(b) still apply. Confirm whether Aetna requires authorization for the specific service and which submission channel applies. If Aetna asks for IUI cycles before IVF and IUI is clinically inappropriate for the patient, include a written contraindication statement from the treating REI with the request. Confirm whether FET and PGT need authorizations separate from the retrieval PA, and record the validity period stated on each approval.
• Cigna New Jersey — Confirm whether Cigna requires authorization for the specific service on the patient's NJ fully insured plan, and whether it asks for IUI cycles before IVF. For NJ patients where IUI is contraindicated (bilateral tubal occlusion, severe male factor, prior repeated IUI failures), submit a physician-authored contraindication statement with the IVF PA package. If Cigna denies an IVF request based on an IUI prerequisite that is clinically inapplicable, appeal on NJ mandate compliance grounds: the statute, as amended by P.L.2023, c.258, requires utilization review decisions to be consistent with ASRM guidelines, and a categorically contraindicated prerequisite is not. Record the validity period stated on each Cigna approval and confirm whether FET and PGT need separate authorizations.
• UnitedHealthcare New Jersey — Confirm at eligibility verification whether UHC requires authorization for the specific service on the patient's NJ fully insured plan and which team or vendor receives it; an authorization sent to the wrong channel may not attach to the claim. Ask which clinical documentation UHC expects; a typical package covers documented infertility meeting the statutory definition, prior treatment history, and the physician's treatment plan. Confirm whether FET, PGT and IUI need authorizations separate from the IVF retrieval authorization, and record the validity period stated on each approval. Confirm whether the specific UHC plan is fully insured and subject to the NJ mandate or is a self-funded national plan — UHC administers both in New Jersey, and the coverage obligation differs substantially.
• AmeriHealth New Jersey — AmeriHealth's fully insured NJ contracts for groups of more than 50 are subject to the mandate. Confirm whether AmeriHealth requires authorization for the specific service and how to submit it. Coverage rules for AmeriHealth NJ mandate-compliant plans follow the amended NJ statute. Confirm network status and PA protocols with AmeriHealth provider relations annually, as regional carrier UM processes evolve and may differ from national carrier workflows in important respects.
• Individual and small-group plans, whichever carrier issues them — The NJ infertility mandate sections apply to contracts for groups of more than 50, so do not assume an individual or small-group plan carries mandate IVF coverage. Confirm the scope of fertility coverage and any PA requirements in the plan's own documents at eligibility verification.

FET Billing Under the New Jersey Mandate

FET billing is consistently a source of denials under NJ mandate plans because billing staff sometimes apply the IVF retrieval authorization number to FET cycle claims. The FET CPT codes — 89352 (embryo thaw and preparation) and 58974 (embryo transfer) — are outside the scope of an oocyte retrieval authorization (58970). Adjudication systems flag the clinical inconsistency and generate a denial. When the carrier requires authorization for FET, obtain a separate FET authorization and confirm it before FET monitoring begins. The FET authorization should reference the active NJ mandate benefit, include documentation of the embryo inventory and the clinical plan for the transfer cycle, and be confirmed as active before any FET monitoring or preparation claims are billed.

The amended NJ statute covers unlimited embryo transfers in accordance with ASRM guidelines, using single embryo transfer when recommended and deemed medically appropriate, so there is no statutory per-retrieval transfer count to track. Practices should still record which retrieval produced the embryos in each FET cycle, because carriers ask for embryo inventory with the FET PA and an ASRM-inconsistent transfer limit is grounds for appeal. For patients who had IVF retrievals at a prior clinic or under a prior carrier, obtain written records of all prior FET cycles and reconcile with the current insurer before submitting new FET authorizations. Discrepancies between the practice's cycle records and the carrier's benefit tracking are easiest to resolve before a cycle begins — not mid-cycle when the patient is already under monitoring.

Same-Sex Couples and Single Patients Under the NJ Mandate

Since P.L.2023, c.258, the NJ definition of infertility includes the need for medical intervention, including donor gametes or donor embryos, to achieve a pregnancy as an individual or with a partner, and it may not be used to deny or delay treatment regardless of relationship status or sexual orientation. The statute sets no donor insemination cycle count for these patients, and N.J.A.C. 11:4-54.4(a)1 requires coverage of artificial insemination "with no limit as to the number of cycles". What it keeps is the general IVF limit: a carrier may limit IVF to a covered person who "has used all reasonable, less expensive and medically appropriate treatments, as determined by a licensed physician". If a carrier asks for therapeutic donor insemination (TDI) cycles before IVF, get the requirement and the cycle count in writing for that plan, and check it against the rule that the infertility definition may not be used to deny or delay treatment based on relationship status or sexual orientation. When the patient has a medical indication that makes TDI inappropriate, such as severely diminished ovarian reserve or bilateral tubal occlusion, include the treating REI physician's written determination in the request, since the statute ties the less-expensive-treatment test to a licensed physician's judgment.

• Where a carrier applies a TDI requirement, collect records of all prior physician-supervised TDI cycles from every treating facility, not only your own clinic, so the history in the request matches what the carrier asks for
• For reciprocal IVF (same-sex female couple where one partner provides oocytes and the other carries the pregnancy): bill the retrieval cycle under the egg-providing partner's fertility benefit with that partner as the billing patient for CPT 58970; bill the transfer cycle under the recipient partner's fertility benefit; confirm with each carrier how reciprocal IVF is handled under their mandate-compliant products, as billing protocols vary by carrier
• ICD-10 coding for same-sex and single patient IVF with no infertility diagnosis: Z31.83 (encounter for assisted reproductive fertility procedure cycle) first; Z31.89 (encounter for other procreative management) after it; when a concurrent infertility diagnosis is documented, list Z31.83 first with the specific N97.x code after it
• Where a carrier applies a TDI requirement, confirm in writing whether cycles performed at a previous clinic count toward it

Common New Jersey Mandate Billing Errors and Prevention

• Assuming mandate coverage for self-funded plans: ERISA self-funded plans are exempt from New Jersey's mandate regardless of carrier name, group size, or New Jersey address. Confirm fully insured status at every initial eligibility call, document the representative's name and the date, and flag self-funded patients in the billing system before any cycle services are rendered or authorized.
• Applying the IVF retrieval authorization to FET claims: FET CPT codes 89352 and 58974 are outside the scope of a retrieval authorization. Build a mandatory workflow trigger that fires whenever a freeze-all cycle completes, when PGT results are received, or when a fresh transfer is cancelled — when the carrier requires FET authorization, that trigger must start the FET request before any FET monitoring services are scheduled.
• Recording freeze-all cycles as something other than a completed retrieval: A freeze-all cycle is a completed oocyte retrieval and counts toward the four completed egg retrievals regardless of whether a fresh transfer occurred. Every 58970 billed is a retrieval. Ensure freeze-all cycles increment the retrieval counter in your benefit tracking system, not just the cryopreservation record.
• Accepting a transfer-count limit on a mandate plan: As amended by P.L.2023, c.258, the statute covers unlimited embryo transfers in accordance with ASRM guidelines. A PA denial that cites a per-retrieval or lifetime transfer cap on a fully insured NJ large-group contract should be appealed rather than converted to patient liability. Keep a per-patient FET ledger attributed to the originating retrieval so the embryo inventory in the PA package is accurate.
• Billing PGT biopsy codes under the IVF retrieval authorization: confirm at the pre-cycle eligibility call whether the carrier requires a separate authorization for CPT 89290 and 89291. Where it does, make PGT authorization a required pre-cycle workflow step whenever PGT is planned, and verify the PGT authorization number is on file before the biopsy claim is submitted.
• Using N97.x infertility diagnosis codes for iatrogenic fertility preservation: Applying an infertility diagnosis to a patient undergoing egg freezing before chemotherapy routes the claim to infertility medical necessity criteria that the patient cannot satisfy. List Z31.84 first and the oncology diagnosis code after it on all iatrogenic preservation claims. Build a clinical intake trigger that identifies patients referred for gonadotoxic therapy and routes their claims to the iatrogenic preservation coding protocol.
• Incomplete prior-treatment documentation in same-sex or single patient requests: When a carrier applies a TDI or other less-expensive-treatment requirement, a request without records from all prior treating facilities is likely to come back for more information. Build prior-treatment record collection into intake for these patients, with a completion date tied to the planned request date.
• Not challenging Cigna's IUI prerequisite when the patient has a clinical contraindication: If Cigna asks for IUI cycles before IVF for a patient whose presentation makes IUI inappropriate, do not simply schedule them. Include a physician-authored contraindication statement in the PA package. If the PA is denied for failure to complete IUI cycles that were clinically contraindicated, appeal on NJ mandate compliance grounds — the amended statute requires utilization review decisions to be consistent with ASRM guidelines, which a clinically unsupportable prerequisite is not.

Appealing New Jersey Mandate Coverage Denials

External review of adverse utilization management determinations by NJ carriers runs through the Independent Health Care Appeals Program (IHCAP), which DOBI administers under the New Jersey Health Care Quality Act, N.J.S.A. 26:2S-11 and 12. Since January 1, 2022, applications go directly to the contracted independent utilization review organization, Maximus Federal Services. The internal appeal must be completed first, unless the carrier missed its own appeal timeframes, waived internal review, or an expedited external review was requested at the same time as an expedited internal review. Take the internal appeal filing deadline from the carrier's denial letter, not a rule of thumb. DOBI states that standard external appeals are decided within 45 calendar days of the request and expedited appeals within 48 hours, and that the decision binds the covered person and the carrier, except to the extent other State or Federal remedies are available. A provider filing for a patient needs the patient's consent. IHCAP does not accept appeals for self-funded plans, Medicare or Medicare Advantage, or contracts delivered in another state; self-funded ERISA plans follow the federal external review process instead.

For NJ mandate medical necessity denials, the internal appeal package should include: complete infertility workup documentation establishing diagnosis and etiology under the NJ statutory definition; prior treatment history relevant to the proposed service; the treating REI physician's signed letter of medical necessity; applicable ASRM Practice Committee Opinion guidelines supporting the requested service for the patient's specific diagnosis; peer-reviewed literature; and a written argument identifying where the carrier's denial conflicts with the NJ infertility statute for that carrier type (for example N.J.S.A. 17B:27-46.1x or 26:2J-4.23, as amended by P.L.2023, c.258) and the patient's covered benefit. For denials applying a clinical prerequisite such as mandatory IUI cycles to a patient for whom those cycles are medically contraindicated, include the physician's contraindication statement and explicitly cite the statutory requirement that utilization review decisions be consistent with ASRM guidelines. For a time-sensitive medical necessity denial, ask the carrier whether a peer-to-peer review with its medical director is available and what the request window is. Document the verbal outcome of the P2P immediately after the call, and follow up in writing if a revised authorization does not arrive.

Quarterly Billing Audit Checklist for New Jersey Practices

A structured quarterly audit of NJ mandate billing should verify: every IVF retrieval, FET, and PGT claim for which the carrier requires authorization has a matching, cycle-specific authorization number on file before submission; FET claims do not reuse the IVF retrieval authorization number where the carrier authorizes FET separately; plan funding type is documented as fully insured at the patient level and confirmed before any cycle services are rendered; per-patient retrieval cycle counters are accurate, reflect all retrievals from all prior carriers and facilities, and are reconciled against the carrier's records at the start of each new retrieval PA submission; per-patient FET records attribute each transfer to its originating retrieval, and any transfer-count denial on a mandate plan has been appealed; same-sex and single patient files contain any prior-treatment records the carrier's written requirement calls for, collected before the request date; PGT biopsy claims reference a PGT-specific authorization wherever the carrier requires one; iatrogenic preservation claims list Z31.84 first with the oncology diagnosis after it and never use N97.x infertility codes; denial-to-internal-appeal turnaround times are within plan-specific internal appeal deadlines; and external review eligibility is tracked for all internally upheld denials to ensure NJ DOBI appeal rights are not forfeited by missing the submission deadline.